Clinical Pharmacology & Therapeutics - Clinical Pharmacogenomics: Opportunities and Challenges at Point of Care

full-text ►
Clinical Pharmacology & Therapeutics - Clinical Pharmacogenomics: Opportunities and Challenges at Point of Care

Clinical Pharmacology & Therapeutics (2013); 93 1, 33–35. doi:10.1038/clpt.2012.196

Clinical Pharmacogenomics: Opportunities and Challenges at Point of Care

S A Scott¹

¹Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, USA

Correspondence: SA Scott, (stuart.scott@mssm.edu)

Received 16 August 2012; Accepted 2 October 2012
Advance online publication 5 December 2012

One of the major barriers to implementing clinical pharmacogenomics has been the efficient integration of rapid turnaround-time genetic testing into routine clinical practice. To address this specific challenge, both point-of-care and preemptive pharmacogenomic testing programs, initially centered on cardiovascular pharmacogenomics, have recently been deployed. Early results indicate that these strategies are feasible and probably beneficial clinically; however, despite these exciting advances toward implementing clinical pharmacogenomics, challenges to widespread adoption remain.